After spending decades in the shadows, psychedelics and empathogens have slowly reemerged as an effective treatment option for a wide variety of behavioral health issues including depression, anxiety, PTSD, chronic inflammation and addiction. With the cannabis legalization movement creeping towards maturity, American society has moved towards a more open-minded approach when it comes to this family of drugs that remain legally classified as a Schedule I substance under the Controlled Substances Act as the potential to provide relief to millions of afflicted people is an opportunity to large to ignore.
With a regulatory pathway already established, the next barrier is funding, but in order to drive greater investment, all interested parties must first understand the opportunity; from size and scope to models and applications.
Momentum’s Psychedelic Opportunity Summit has been designed to provide attendees with the scientific, medical, regulatory, economic, cultural and entrepreneurial knowledge need to determine an investment strategy. Whether you’re an investor, an insurance company, a pharmaceutical company, hospital system or entrepreneur, there is opportunity in the use of psychedelics to address a range of ailments including depression, anxiety, addiction, PTSD, chronic inflammation and alzheimers.
Attend this conference you will gain real world knowledge from industry veterans, experts, medical professionals and entrepreneurs including:
- The Current State of Psychedelic Affairs, Research, Trials, and Conclusions
- The Legal and Regulatory Environment for Psychedelics
- Effectively Running Clinical Trials with a Psychedelic and Therapy Support
- Economic Modeling
- Current and Potential Future Innovations in Mental Health Care
- Theoretical Incorporation of Psychedelic Treatment Into the US Payer Ecosystem
The Psychedelic Opportunity Summit was founded by Momentum’s CEO Ben Greenzweig who’s passionate purpose is mental health. While developing conferences has been his speciality for more than two decades, as an open depressive who blogs and talks openly about his battles in hope of breaking down the stigma, Ben’s curiosity about his disease led him on a journey to discover the therapeutic potential of psychedelics and empathogens. It is from this passion that forged his determination to do his part to support the responsible growth of this industry and provide a way to help many, like him, who suffer.
